Autopsy report · NCT04812106

Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program

“Sponsor decision not related to safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 4 months before it started.
• Ran for about 3 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Ultragenyx Pharmaceutical Inc

Sponsor type

Industry

Conditions

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Interventions

No Intervention

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
  “Sponsor decision not related to safety reasons” (96% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (92% match in meaning)
• A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts
  “Sponsor decision, not safety related” (92% match in meaning)
• Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
  “Sponsor decision; the decision is not related to any safety concern.” (92% match in meaning)
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
  “Sponsor decision, not for safety reasons.” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.